Dynavax Technologies Stock Price, News & Analysis (NASDAQ:DVAX)

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DVAX shares.
View DVAX analyst ratings or view top-rated stocks.

2 analysts have issued 12-month price objectives for Dynavax Technologies' shares. Their DVAX share price targets range from $27.00 to $28.00. On average, they predict the company's share price to reach $27.50 in the next twelve months. This suggests a possible upside of 106.6% from the stock's current price.
View analysts price targets for DVAX or view top-rated stocks among Wall Street analysts.

Dynavax Technologies' stock was trading at $10.64 at the beginning of 2023. Since then, DVAX stock has increased by 25.1% and is now trading at $13.31.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our DVAX earnings forecast.

Dynavax Technologies Co. (NASDAQ:DVAX) announced its quarterly earnings data on Thursday, November, 2nd. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.11. The biopharmaceutical company earned $69.51 million during the quarter, compared to analysts' expectations of $62.15 million. Dynavax Technologies had a net margin of 16.92% and a trailing twelve-month return on equity of 10.51%.

ETFs with the largest weight of Dynavax Technologies (NASDAQ:DVAX) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), Invesco Biotechnology & Genome ETF (PBE), Invesco S&P SmallCap Health Care ETF (PSCH), ETC 6 Meridian Small Cap Equity ETF (SIXS), Burney U.S. Factor Rotation ETF (BRNY), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Franklin Genomic Advancements ETF (HELX) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).

13 employees have rated Dynavax Technologies Chief Executive Officer Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among the company's employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 61.0% of employees surveyed would recommend working at Dynavax Technologies to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA).

Dynavax Technologies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Federated Hermes Inc. (9.77%), Chicago Capital LLC (4.50%), Blair William & Co. IL (1.91%), Morgan Stanley (1.58%), Northern Trust Corp (1.12%) and Eventide Asset Management LLC (1.10%). Insiders that own company stock include Andrew A F Hack, David F Novack, David F Novack, Francis Cano, Justin Burgess, Robert Janssen and Ryan Spencer.
View institutional ownership trends.

Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.